RBC Capital analyst Craig Wong-Pan initiated coverage of Fisher & Paykel Healthcare with an Underperform rating and NZ$19 price target. The analyst sees downside risk to consensus estimates and says the stock is trading well above its historical trading ranges. As such, Fisher & Paykel looks expensive relative to comparable companies, Wong-Pan tells investors in a research note.
Published first on TheFly
